← SynDRA
VICRIVIROC
SynDRA canonical compound SYN0003338 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | CCR5 |
|---|
| Mechanism of action | CCK receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- CCK receptor antagonist
- CCR5 ANTAGONIST
- C-C chemokine receptor type 5 antagonist
- CC chemokine receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADGRF1
- GPR119
- TDG
- S1PR1
- NTHL1
- NEIL1
- MUTYH
- MPG
- MBD4
- HDAC6
- GPR35
- GLP1R
- ADRA2A
- FPR2
- FFAR4
- CX3CR1
- CHRM2
- CHRM1
- C5AR1
- APLNR
- AGTR1
- ADRB2
- UNG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- MK-7690
- SCH-417690 FREE BASE
- SCH-D
- SchD
- SCH-417690
- PRO 140 & Vicrivirac
- SCH-D690
- Sch-D compound
- PRO 140 (Anti-CCR5 monoclonal antibody) & 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine
- (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone
- 1-((4,6-Dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine
- 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine
- TL515DW4QS
- MK-4176
- vicrivirocum
- RefChem:934022
- DTXCID301326939
- Vicriviroc [INN]
- VCV
- SCH-D (Old RN)
- UNII-TL515DW4QS
- Vicriviroc (SCH-417690)
- SCH-DS
- starbld0032646
- VICRIVIROC [MI]
- NCGC00182549-01
- VICRIVIROC [WHO-DD]
- MK-4176 intravaginal ring
- GTPL807
- SCHEMBL118885
- orb1740002
- CHEBI:94843
- EX-A4709A
- MK-4176 IVR
- CNPVJJQCETWNEU-CYFREDJKSA-N
- BDBM50145685
- NCGC00182549-07
- NCGC00182549-08
Look up VICRIVIROC in the interactive SynDRA portal →